Product Description
an extract of Panax quinquefolius (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00527969)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CV Technologies
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Multiple Sclerosis|Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00754832 |
NCT00754832 | P2 |
Completed |
Multiple Sclerosis |
2008-09-01 |
2019-03-18 |
Treatments |
|
NCT00527969 |
REMEMBER-fX | P2 |
Completed |
Other |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|